Back
Corporate News
Mankind Pharma’s revenue from operations rose 12.9% to INR 4,031 crore in Q1 2026
30-Jul-2026, 05:09
Mankind Pharma (BSE: 543904 | NSE: MANKIND) announced its financial results for the first quarter ended June 30, 2026, reporting revenue from operations of INR 4,031 crore, a 12.9% year-over-year increase, and a 29.1% rise in profit after tax to INR 574 crore. The company’s EBITDA margin improved to 26.3%, up 250 basis points year-over-year, while its PAT margin increased to 14.2%, up 170 basis points year-over-year, driven by a 11.0% growth in the domestic business (excluding Consumer Health) and a 29.0% increase in exports.
Mankind Pharma (BSE: 543904 | NSE: MANKIND) announced its financial results for the first quarter ended June 30, 2026, reporting revenue from operations of INR 4,031 crore, a 12.9% year-over-year increase, and a 29.1% rise in profit after tax to INR 574 crore. The company’s EBITDA margin improved to 26.3%, up 250 basis points year-over-year, while its PAT margin increased to 14.2%, up 170 basis points year-over-year, driven by a 11.0% growth in the domestic business (excluding Consumer Health) and a 29.0% increase in exports.